Dapagliflozin in patients with heart failure and reduced ejection fraction

被引：0

作者：

Giorgio Colombo

Rosa Casella

Alessia Cazzaniga

Chiara Casiraghi

机构：

[1] Fondazione IRCCS Ca’ Granda,Dipartimento Di Medicina Interna

[2] Ospedale Maggiore Policlinico,UOC Pronto Soccorso e Medicina d’Urgenza

[3] Università degli Studi di Milano,undefined

[4] Fondazione IRCCS Ca’ Granda,undefined

[5] Ospedale Maggiore Policlinico Di Milano,undefined

来源：

Internal and Emergency Medicine | 2020年 / 15卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：515 / 517

页数：2

共 14 条

[1]

Zinman B(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2122

[2]

Wanner C(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357

[3]

Lachin J(2018)SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review Diabetologia 61 2108-2117

[4]

Wiviott SD(2019)Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 116 1944-1947

[5]

Raz I(2015)Impact of funding source on clinical trial results including cardiovascular outcome trials Am J Cardiol undefined undefined-undefined

[6]

Bonaca O(undefined)undefined undefined undefined undefined-undefined

[7]

Verma S(undefined)undefined undefined undefined undefined-undefined

[8]

McMurray JJV(undefined)undefined undefined undefined undefined-undefined

[9]

McMurray JJV(undefined)undefined undefined undefined undefined-undefined

[10]

Solomon SD(undefined)undefined undefined undefined undefined-undefined